Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AskBio Knocks Down Enough Hurdles To Raise $235m For Its Gene Therapy Platform

Apr 12 2019

• By Mandy Jackson

DNA

Related Content

Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'

Oct 12 2018

BioNotebook: Halozyme falters; Baxter acquires Chatham; Celgene buys Acceleron shares; and IPOs lose momentum

Apr 05 2014

Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up

Aug 08 2016

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

Mar 07 2019

Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing

Apr 03 2018

Pfizer Advances Duchenne Drug As It Prioritizes Gene Therapy

Apr 12 2018

Related Companies

Asklepios BioPharmaceutical, Inc.

University of North Carolina

Pfizer Inc.

Baxter International Inc.

Baxalta Incorporated

Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Baxter International Inc.

Medtronic plc

Allogene Therapeutics Inc.

Additional Topics

Financing Gene Therapy Business Strategies Companies Innovation Commercial BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window